HOOKIPA Pharma Inc. (HOOK)
NASDAQ: HOOK · IEX Real-Time Price · USD
6.42
+0.07 (1.10%)
At close: Jul 19, 2024, 4:00 PM
6.38
-0.04 (-0.62%)
Pre-market: Jul 20, 2024, 9:26 AM EDT
HOOKIPA Pharma Revenue
HOOKIPA Pharma had revenue of $53.55M in the twelve months ending March 31, 2024, with 235.12% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $36.60M with 1,052.36% year-over-year growth. In the year 2023, HOOKIPA Pharma had annual revenue of $20.13M with 41.27% growth.
Revenue (ttm)
$53.55M
Revenue Growth
+235.12%
P/S Ratio
1.16
Revenue / Employee
$299,173
Employees
179
Market Cap
61.99M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 20.13M | 5.88M | 41.27% |
Dec 31, 2022 | 14.25M | -4.20M | -22.76% |
Dec 31, 2021 | 18.45M | -1.14M | -5.80% |
Dec 31, 2020 | 19.58M | 7.64M | 63.99% |
Dec 31, 2019 | 11.94M | 4.31M | 56.53% |
Dec 31, 2018 | 7.63M | - | - |
Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionHOOK News
- 14 days ago - HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split - GlobeNewsWire
- 20 days ago - HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV - GlobeNewsWire
- 6 weeks ago - HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting - GlobeNewsWire
- 7 weeks ago - HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab - GlobeNewsWire
- 3 months ago - HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers - GlobeNewsWire